TransMedics Group (NASDAQ:TMDX) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings results on Thursday. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.03), Zacks reports. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group updated its FY 2025 guidance to EPS.

TransMedics Group Stock Down 2.2 %

TMDX stock traded down $1.64 on Thursday, reaching $72.12. 1,995,261 shares of the company traded hands, compared to its average volume of 2,142,666. The company has a market cap of $2.42 billion, a P/E ratio of 76.72 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a one year low of $55.00 and a one year high of $177.37. The firm has a fifty day simple moving average of $67.29 and a 200-day simple moving average of $102.44.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on TMDX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, Piper Sandler cut their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.